Profile data is unavailable for this security.
About the company
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
- Revenue in CHF (TTM)508.61m
- Net income in CHF72.42m
- Incorporated2003
- Employees2.20k
- LocationYpsomed Holding AGBrunnmattstrasse 6BURGDORF 3401SwitzerlandCHE
- Phone+41 344244111
- Fax+41 344244122
- Websitehttps://www.ypsomed.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medacta Group SA | 498.78m | 46.25m | 2.25bn | 1.73k | 48.64 | 6.96 | 21.79 | 4.51 | 2.31 | 2.31 | 24.95 | 16.17 | 0.7979 | 0.8708 | 5.92 | 288,312.70 | 7.40 | 7.89 | 9.09 | 10.57 | 68.10 | 70.43 | 9.27 | 10.09 | 0.9004 | 4.80 | 0.3817 | 17.01 | 16.85 | 13.38 | 2.41 | 0.6937 | 8.32 | -- |
| Elekta AB (publ) | 1.53bn | 120.03m | 2.38bn | 4.58k | 20.57 | 2.87 | 11.20 | 1.56 | 3.74 | 3.74 | 47.60 | 26.82 | 0.6208 | 3.29 | 2.90 | 4,150,570.00 | 4.89 | 4.32 | 8.69 | 7.89 | 37.90 | 39.93 | 7.88 | 7.68 | 0.8219 | 4.02 | 0.4106 | 65.79 | 15.95 | 7.83 | -18.28 | -6.90 | 12.86 | 11.38 |
| Ambu A/S | 641.37m | 31.17m | 3.48bn | 4.70k | 125.36 | 5.55 | 44.70 | 5.42 | 0.9014 | 0.9014 | 18.71 | 20.36 | 0.7075 | 2.00 | 7.26 | 1,060,875.00 | 3.44 | 3.81 | 3.97 | 4.62 | 56.97 | 59.37 | 4.86 | 5.43 | 1.30 | 7.20 | 0.1038 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| GN Store Nord A/S | 2.38bn | 70.20m | 4.12bn | 7.05k | 56.42 | 3.05 | 13.87 | 1.73 | 3.70 | 3.70 | 127.04 | 68.44 | 0.6139 | 3.00 | 4.73 | 2,541,382.00 | 1.94 | 4.91 | 3.22 | 7.44 | 50.50 | 53.29 | 3.16 | 6.82 | 0.4118 | 2.50 | 0.5582 | 36.84 | -3.03 | 11.30 | -55.38 | -28.74 | 7.53 | -- |
| Ypsomed Holding AG | 508.61m | 72.42m | 4.48bn | 2.20k | 61.75 | 7.80 | 29.95 | 8.80 | 5.31 | 5.31 | 37.31 | 42.03 | 0.5888 | 4.92 | 5.75 | 247,016.00 | 8.38 | 4.44 | 12.70 | 6.77 | 32.04 | 26.95 | 14.24 | 6.87 | 0.5577 | 30.61 | 0.2614 | 18.54 | 7.02 | 1.31 | 121.92 | -0.3034 | 20.32 | -1.47 |
| Getinge AB | 2.70bn | 191.31m | 4.94bn | 11.86k | 27.65 | 1.95 | 14.89 | 1.83 | 8.39 | 8.39 | 118.22 | 118.80 | 0.6001 | 2.53 | 6.79 | 2,742,908.00 | 4.29 | 5.31 | 5.56 | 6.98 | 45.37 | 47.83 | 7.15 | 8.69 | 0.7569 | 11.47 | 0.2035 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| SCHOTT Pharma AG & Co KgaA | 884.62m | 154.44m | 5.55bn | 4.65k | 35.91 | 7.89 | 27.43 | 6.27 | 1.05 | 1.05 | 6.01 | 4.78 | -- | -- | -- | 194,928.30 | -- | -- | -- | -- | 35.23 | -- | 17.48 | -- | 1.08 | -- | 0.094 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| ConvaTec Group PLC | 1.95bn | 118.68m | 5.83bn | 10.13k | 49.22 | 3.78 | 18.55 | 2.99 | 0.0507 | 0.0507 | 0.8329 | 0.659 | 0.5865 | 2.57 | 6.14 | 168,790.40 | 3.57 | 2.36 | 4.18 | 2.73 | 56.04 | 55.03 | 6.08 | 4.34 | 0.8835 | 2.65 | 0.4367 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 169.06k | 1.24% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 162.83k | 1.19% |
| Premier Fund Managers Ltd.as of 30 Nov 2023 | 138.72k | 1.02% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 132.39k | 0.97% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 125.90k | 0.92% |
| GAM Investment Management (Switzerland) AGas of 31 Oct 2023 | 115.26k | 0.84% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 99.97k | 0.73% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 92.41k | 0.68% |
| VV Verm�gensverwaltung AGas of 31 Jan 2024 | 90.28k | 0.66% |
| Vontobel Asset Management AGas of 29 Dec 2023 | 69.01k | 0.51% |
